Eur Rev Med Pharmacol Sci 2019; 23 (1): 44-51

DOI: 10.26355/eurrev_201901_16746

miR-152 promotes spinal cord injury recovery via c-jun amino terminal kinase pathway

T. Zhang, G. Gao, F. Chang

Department of Orthopaedic Surgery, Affiliated Shanxi Provincial People’s Hospital, Shanxi Medical University, Taiyuan, China. yanjun8404@163.com


OBJECTIVE: The aim of this research is to explore the possible role of miR-152 in spinal cord injury and its underlying mechanism.

MATERIALS AND METHODS: After a mouse model of spinal cord injury (SCI) was developed, Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was used to detect the expression of miR-152 and c-jun in the mouse. In addition, the expression levels of interleukin-1b (IL-1b), interleukin-18 (IL-18) and tumor necrosis factor-α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA). Subsequently, miR-152 was overexpressed and the levels of inflammation and c-jun after spinal cord injury were detected by Western blot. Furthermore, the grip strength of double forelimb, left forelimb or right forelimb of the mice was detected using a grip force test after miR-152 was overexpressed in the injured area of each group.

RESULTS: By constructing a mouse model of spinal cord injury, we found that the expression of miR-152 in the injured area decreased with time; meanwhile, the inflammatory relative genes including IL-1b, IL18, TNF-α, and c-jun were significantly increased. However, miR-152 overexpression significantly reduced the levels of inflammation genes as well as the expression of c-jun. Besides, the strength of the forelimbs in the spinal cord injury mice was restored.

CONCLUSIONS: MiR-152 could inhibit inflammatory responses and promote the recovery of the spinal cord injury through the c-jun N-terminal kinase pathway and it can be a target molecular for treating spinal cord injury.

Free PDF Download

To cite this article

T. Zhang, G. Gao, F. Chang
miR-152 promotes spinal cord injury recovery via c-jun amino terminal kinase pathway

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 1
Pages: 44-51
DOI: 10.26355/eurrev_201901_16746